News about Global Pharma

PerkinElmer to acquire Nexcelom Bioscience for US$ 260 million

PerkinElmer to acquire Nexcelom Bioscience for US$ 260 million

Nexcelom is a leading, global provider of automated cell counting instruments, image cytometry workstations, assays and a variety of cell reagents, consumables, and fit-for-purpose cell counting method selection and development instructions that follow ISO Cell Counting Standards and aid in the development of cell and gene and immuno-oncology therapies

Global Pharma | 14/05/2021 | By Darshana

Lilly gives out licences for Covid-19 drug Baricitinib to Dr Reddy's, MSN Labs and Torrent Pharmac

Lilly gives out licences  for Covid-19 drug Baricitinib to Dr Reddy's, MSN Labs and Torrent Pharmac

Eli Lilly and Company announced that it has issued additional royalty-free, non-exclusive voluntary licenses to established Indian pharma manufacturers of generic medicines, Dr Reddy?s, MSN Laboratories and Torrent Pharmaceuticals, who will be collaborating with Lilly to accelerate and expand the availability of baricitinib in India

Global Pharma | 13/05/2021 | By Darshana

To Treat CNS and Neuromuscular Disorders, Biogen Inks Research Pact with Capsigen to Discover and Develop Novel AAV Capsids

To Treat CNS and Neuromuscular Disorders,  Biogen Inks Research Pact with Capsigen to Discover and Develop Novel AAV Capsids

Biogen and Capsigen announced that they have entered into a strategic research collaboration, Capsigen?s proprietary TRADE platform and associated technologies will be utilized with the aim to create and identify novel AAV capsids tailored to meet disease-specific transduction profiles.

Global Pharma | 12/05/2021 | By Hemant

Dr Reddy's Lab launches Avigan for COVID-19 treatment

Dr Reddy's Lab launches Avigan for COVID-19 treatment

Dr Reddy's Laboratories Ltd announced the launch of Avigan (favipiravir) 200 mg tablets in India for the treatment of patients with mild to moderate COVID-19 disease

Global Pharma | 19/08/2020 | By Darshana 401

Aurobindo Pharma Q1 net profit rises by 22.8% to Rs. 780.6 crore

Aurobindo Pharma Q1 net profit rises by 22.8% to Rs. 780.6 crore

Aurobindo Pharma registered a 22.8 per cent year-on-year rise in net profit at Rs. 780.6 crore for the first quarter ended June 2020

Global Pharma | 13/08/2020 | By Darshana 156

FDA Posts Interim Results from Required Essure Postmarket Surveillance Study

FDA Posts Interim Results from Required Essure Postmarket Surveillance Study

?Although Essure is no longer available for implantation in the U.S., the FDA remains committed to evaluating long-term safety information in women who have received the device, including data from an FDA-required postmarket surveillance study.?

Global Pharma | 10/07/2020 | By Darshana 182

FDA issues warning letters to two breast implant manufacturers as part of ongoing efforts to protect patients

FDA issues warning letters to two breast implant manufacturers as part of ongoing efforts to protect patients

Today, the U.S. Food and Drug Administration issued warning letters to two breast implant manufacturers for failure to comply with various regulatory requirements

Global Pharma | 15/05/2020 | By Darshana 203

Merck?s foundational CRISPR-Cas9 technology receives US patnet

Merck?s foundational CRISPR-Cas9 technology receives US patnet

Merck, a leading science and technology company, announced that two of its CRISPR-Cas9-assisted genome-editing patents have been allowed in the United States

Global Pharma | 12/05/2020 | By Darshana 189

FDA Authorizes First Antigen Test to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients

FDA Authorizes First Antigen Test to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients

The U.S. Food and Drug Administration has issued the first emergency use authorization (EUA) for a COVID-19 antigen test, a new category of tests for use in the ongoing pandemic

Global Pharma | 10/05/2020 | By Darshana 172

FDA Continues to Combat Fraudulent COVID-19 Medical Products

FDA Continues to Combat Fraudulent COVID-19 Medical Products

Today, the U.S. Food and Drug Administration is providing an update on the agency?s efforts to combat the extremely concerning actions by companies and individuals that are exploiting or taking advantage of widespread fear among consumers during the COVID-19 pandemic

Global Pharma | 08/05/2020 | By Darshana 158

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology